Amgen Reports Phase 2 Data for Durvalumab in Obesity

Amgen today announced Phase 2 results for durvalumab in patients with obesity. The study demonstrated that durvalumab reduces biomarker levels compared to standard of care or placebo. These results provide important insights into the treatment of obesity and support the continued development of durvalumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.